We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Turns to IOM for Advice on Ethics in Monitoring Postmarket Drug Safety
FDA Turns to IOM for Advice on Ethics in Monitoring Postmarket Drug Safety
June 9, 2010
The FDA is asking the Institute of Medicine (IOM) for advice on ethical issues in postmarket drug safety, including a framework for weighing different kinds of safety evidence when considering options for postmarket regulatory action.